Also from this source


22 Jun, 2017, 15:52 ET AbbVie Declares Quarterly Dividend

You just read:

CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)

News provided by

AbbVie

25 Jul, 2016, 04:00 ET